Asymmetric synthesis of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one derivatives, potent and selective NOP agonists

Tetrahedron

Volumn 64, Issue 14, 2008, Pages 3119-3126

  Clark, John K ^a   Jones, Philip S ^a   Palin, Ronald ^a   Rosair, Georgina ^b   Weston, Mark ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

Asymmetric hydrogenation; Chiral reduction; NOP ORL1 agonist; Noyori catalyst

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 2 (3 (1 [3 (5 METHOXY 2 METHYL PHENOXY) 4 EMTHYL PENTYL] PIPERIDIN 4YL) 2 OXO 2,3 DIHYDRO BENZIMIDAZOL 1 YL) N METHYL ACETAMIDE; ACETAMIDE DERIVATIVE; ACETIC ACID DERIVATIVE; BENZIMIDAZOLE; METHYL ISOBUTYRYL ACETATE; N 3 PHENOXYPROPYL PIPERIDINE BENZIMIDAZOL 2 ONE DERIVATIVE; OPIATE ANTAGONIST; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; ASYMMETRIC SYNTHESIS; ATMOSPHERIC PRESSURE; CHIRALITY; DRUG SCREENING; DRUG STRUCTURE; HYDROGENATION; MITSUNOBU REACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

EID: 39749146977     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2008.01.125     Document Type: Article

References (44)

1. (a) R.K. Reinscheid H.P. Nothacker A. Bourson A. Ardati R.A. Henningsen J.R. Bunzow D.K. Grandy H. Langen F.J. Monsma O. Civelli Jr. Science 270 1995 792
2. (b) J.-C. Meunier C. Mollereau L. Toll C. Suaudeau C. Moisand P. Alvinerie J.L. Butour J.C. Guillemot P. Fexrara B. Monsarrat H. Mazarguil G. Vussart M. Parmentier J. Costentin Nature 377 1995 532
3. (c) J.E. Grisel J.S. Mogil Peptides 21 2000 1037
4. (a) J.-C. Meunier Exp. Opin. Ther. Patents 10 2000 371 and references therein
5. (b) G. Calo R. Guerrini A. Rizzi S. Salvadori D. Regoli Br. J. Pharmacol. 129 2000 1261 and references therein
6. (c) C.N. Allen Z.-G. Jiang K. Teshima T. Darland M. Ikeda C.S. Nelson D.I. Quigley T. Yoshioka R.G. Allen M.A. Rea D.K. Grandy J. Neurosci. 19 1999 2152
7. J.S. Mogil G.W. Pasternak Pharmacol. Rev. 53 2001 381
8. (a) H.J. McQuay D. Carroll R.A. Moore J. Pain Symptom Manag. 17 1999 164
9. (b) G.A. Jelinek BMJ 321 2000 1236
10. J. Lötsch R. Dudziak R. Freynhagen J. Marschner G. Geisslinger Clin. Pharmacokinet. 45 2006 1051
11. S.L. Waller M. Bailey Lancet 2 1987 801
12. (a) S. Ronzoni I. Peretto G.A.M. Giardina Exp. Opin. Ther. Patents 11 2001 525
13. (b) G.C. Bignan P.J. Connolly S.A. Middleton Exp. Opin. Ther. Patents 15 2005 357
14. (c) N. Zaveri Life Sci. 73 2003 663
15. (d) D. Barlocco L. Toma G. Cignarella Mini-Rev. Med. Chem. 1 2001 363
16. (a) S. Ozaki H. Kawamoto Y. Itoh M. Miyaji T. Azuma D. Ichikawa H. Nambu T. Iguchi Y. Iwasawa H. Ohta Eur. J. Pharmacol. 402 2000 45
17. (b) S. Ozaki H. Kawamoto Y. Itoh M. Miyaji Y. Iwasawa H. Ohta Eur. J. Pharmacol. 387 2000 R17
18. (c) H. Kawamoto S. Ozaki Y. Itoh M. Miyaji S. Arai H. Nakashima T. Kato H. Ohta Y. Iwasawa J. Med. Chem. 42 1999 5061
19. (d) H. Kawamoto H. Nakashima T. Kato S. Arai K. Kamata Y. Iwasawa Tetrahedron 57 2001 981
20. (e) C. De Risi G.P. Pollini C. Trapella I. Peretto S. Ronzoni G.A.M. Giardina Bioorg. Med. Chem. 9 2001 1871
21. (a) J. Wichmann G. Adam S. Rover M. Hennig M. Scalone A.M. Cesura F.M. Dautzenburg F. Jenck Eur. J. Med. Chem. 35 2000 839
22. (b) F. Jenck J. Wichmann F.M. Dautzenburg J.-L. Moreau A.M. Ouagazzal J.R. Martin K. Lundstrom A.M. Cesura S.M. Poli S. Rover S. Kolczewski G. Adam G.J. Kilpatrick Proc. Natl. Acad. Sci. U.S.A. 97 2000 4938
23. C. Thomsen R. Hohlweg Br. J. Pharmacol. 131 2000 903
24. F.M. Dautzenberg J. Wichmann J. Higelin G. Py-Lang C. Kratzeisen P. Malherbe G.J. Kilpatrick F. Jenck J. Pharmacol. Exp. Ther. 298 2001 812
25. (a) R. Palin D.R. Barn J.K. Clark J.E. Cottney P.M. Cowley M. Crockatt L. Evans H. Feilden R.R. Goodwin F. Griekspoor S.J.A. Grove A.K. Houghton P.S. Jones R.J. Morphy A.R.C. Smith H. Sundaram D. Vrolijk M.A. Weston G. Wishart P. Wren Bioorg. Med. Chem. Lett. 15 2005 589
26. (b) R. Palin A. Bom J.K. Clark L. Evans H. Feilden A.K. Houghton P.S. Jones B. Montgomery M.A. Weston G. Wishart Bioorg. Med. Chem. 15 2007 1828
27. (c) Cowley, P. M.; Cottney, J.; Barn, D. R.; Morphy, J. R.; Palin, R.; Grove, S. J. A. PCT Int. Application, WO 2002100861, 2002.
28. (a) O. Mitsunobu Synthesis 1981 1
29. (b) D.L. Hughes Org. React. 42 1992 335
30. (c) D.L. Hughes Org. Prep. 28 1996 127
31. J.P. Genet V. Ratovelomanana-Vidal M.C. Cano de Andrade X. Pfister P. Guerreiro J.Y. Lenoir Tetrahedron Lett. 36 1995 4801
32. (a) M. Kitamura M. Tokunaga T. Ohkuma R. Noyori Org. Synth. 71 1993 1
33. (b) M. Kitamura Y. Hsiao M. Ohta M. Tsukamoto T. Ohta H. Takaya R. Noyori J. Org. Chem. 59 1994 297
34. (c) M. Kitamura T. Ohkuma S. Inoue N. Sayo H. Kumobayashi S. Akutagawa T. Ohta H. Takaya R. Noyori J. Am. Chem. Soc. 110 1988 629
35. R. Noyori M. Ohta Y. Hsiao M. Kitamura T. Ohta H. Takaya J. Am. Chem. Soc. 108 1986 7117
36. A. Albert D. Seebach E. Duchardt H. Schwalbe Helv. Chim. Acta 85 2002 633
37. R. Noyori T. Ohkuma M. Kitamura H. Takaya N. Sayo H. Kumobayashi S. Akutagawa J. Am. Chem. Soc. 109 1987 5856
38. 2-Methyl-5-methoxy phenol was prepared according to S. Ram L.D. Spicer Tetrahedron Lett. 29 1988 3741
39. The yield can be increased to 44% with only 4% of the isoprenyl by-product when ADDP is used in place of DIAD and added over 2 h. See:
40. (a) B.H. Lipshutz D.W. Chung B. Rich R. Corral Org. Lett. 8 2006 5069
41. (b) S.D. Lepore Y. He J. Org. Chem. 68 2003 8261
42. T. Ladduwahetty R. Baker M.A. Cascieri M.S. Chambers K. Haworth L.E. Keown J.M. MacIntyre S. Owen W. Rycroft S. Sadowski E.M. Seward S.L. Shepheard C.J. Swain F.D. Tattersall A.P. Watt D.W. Williamson R.J. Hargreaves J. Med. Chem. 39 1996 2907
43. XSCANS Version 2.2 1996 Bruker AXS Madison, WI
44. G.M. Sheldrick SHELXTL 5.1. Version 5.1 1999 Bruker AXS Madison, Wisconsin, USA